Latest news with #JubilantPharmova
&w=3840&q=100)
Business Standard
21-05-2025
- Business
- Business Standard
Pharma shares in focus; GSK, Jubilant, Eris, Gland, Torrent rally up to 8%
Shares of pharmaceutical companies were in demand, and rallied up to 8 per cent on the bourses in Wednesday's intra-day trade on healthy growth outlook. In-line March quarter performance, coupled with Torrent Pharma and Gland Pharma's optimistic FY26 guidance led the up move in pharma stocks. GlaxoSmithKline Pharmaceuticals (GSK Pharma), Ajanta Pharma, Gland Pharma, Jubilant Pharmova, Torrent Pharmaceuticals, Natco Pharma, Aurobindo Pharma, Lupin, Ipca Labs, Dr Reddy's Laboratories, Cipla, Divi's Laboratories, Granules India and Sun Pharmaceutical were up in the range of 2 per cent to 8 per cent in intra-day trade. At 09:52 AM; the Nifty Pharma, the top gainer among sectoral indices, was up 1.6 per cent, as compared to 0.56 per cent rise in the Nifty 50. The pharma index rallied 2.3 per cent in intra-day trade today. The Indian pharmaceutical market (IPM) reported growth of 7.4 per cent year-on-year (YoY) in April 2025 on a base of 9.5 per cent YoY growth in April 2024. IPM growth in Moving Annual Turnover (MAT) April 2025 stood at 7.9 per cent YoY versus 7.3 per cent YoY growth in MAT April 2024, with volumes contributing 130 bps, much higher than the nil contribution in MAT April 2024. India Ratings and Research (Ind-Ra), part of the Fitch Group, said the continued revenue growth was driven by companies' price hikes, with volume growing 1.3 per cent year-on-year (YoY). 'India Ratings expects IPM to grow 7-8 per cent YoY during the financial year 2025-26 (FY26) with sustained growth momentum in the chronic therapies, led by price increases and product launches', said Nishith Sanghvi, director, corporate ratings, India Ratings. Kotak Institutional Equities highlights that, although pricing contributed to the bulk of the growth, volume traction in the end-market still remains sluggish. However, the brokerage firm expects a slightly stronger acute season along with pricing, acquisitions and in-licensing deals to drive 10 per cent-23 per cent YoY growth in FY2026E domestic sales for its coverage. ALSO READ | Meanwhile, Ind-Ra opines the executive order to reduce the prices of prescription drugs in the US, once implemented, will have limited near-term impact on the Indian pharma companies, but it may have a bearing on their long-term capital allocation strategies. According to media reports, on 12 May 2025, the US President declared that he would be signing an executive order that would reduce the prices of prescription drug and pharmaceutical products' prices by 30 per cent to 80 per cent. Additionally, the executive order would establish a Most Favoured Nation Policy whereby the US would pay the same price as the country that pays the lowest price anywhere in the world. Jubilant Pharmova said the large innovator pharma companies, for their US requirements, are now looking to create an alternate manufacturing site in the US as a risk management measure in the event of tariff imposed by the US government. Therefore, the company is starting to see excellent traction in the Contract Development and Manufacturing Organization (CDMO) Sterile Injectable business for new lines in the Spokane facility. The company expects to reach peak utilisation for Line 3 in 3 years from start of commercial production vs 4 years, expected earlier. Among individual stocks, GSK Pharma soared 8 per cent to ₹ 3,012.20 in intra-day trade. The management said the company remains committed to delivering sustained above-market growth and strong shareholder returns. In FY2025-26, GSK Pharma will continue to focus on its innovative portfolio through the launch of oncology assets. The company said it is on track to launch Zejula (Niraparib), a PARP inhibitor for ovarian cancer and Jemperli (Dostarlimab), an immunotherapy approved for the second-line treatment of endometrial cancer. In January to March 2025 quarter (Q4FY25), Torrent Pharma's domestic business continued to post strong double-digit growth despite the slowdown in the overall market. Growth in the US business has started to show signs of a pickup. Meanwhile, the management of Gland Pharma named a few additional growth drivers for the medium term. These include complex injectables for the US market, biosimilar CDMO business in India and GLP-1 CDMO in Cenexi. The company has already entered into agreements with Dr Reddy's Labs in India and another pharma company in China for biosimilar CDMO.
Time of India
21-05-2025
- Business
- Time of India
Top stocks to buy today: Stock recommendations for May 21, 2025
Top stocks to buy today (AI image) Stock market recommendations : According to Mehul Kothari, DVP - Technical Research, Anand Rathi Shares and Stock Brokers, Chennai Petro, Jubilant Pharmova, and ONGC are the top stocks to buy today: CHENNAI PETRO: BUY NEAR ₹670 | Stop Loss: ₹570 | Target: ₹870 (3 Months) Chennai Petro has broken out of a prolonged consolidation phase, forming a classic inverse head and shoulders pattern. The breakout is supported by strong volumes and has occurred above the 200 DEMA, adding strength to the bullish structure. A positive crossover in ADX (14) and a breakout in the weekly RSI suggest trend initiation and fresh momentum. Traders may consider entering near ₹670 with a stop-loss at ₹570 and a target of ₹870 over the next 3 months. JUBILANT PHARMOVA: BUY NEAR ₹980 | Stop Loss: ₹940 | Target: ₹1060 (Short Term) Jubilant Pharmova has broken out above a previous swing high, confirming a range breakout. A double bottom formation is visible on the charts, and RSI has shown a range shift above 60, which indicates bullish momentum. Traders can look to enter on dips near ₹980, keeping a stop-loss at ₹940 and targeting ₹1060 in the short term. ONGC: BUY NEAR ₹250 | Stop Loss: ₹244 | Target: ₹260 (Short Term) ONGC has also witnessed a breakout from its recent trading range. The stock has successfully reclaimed its 200 DEMA, a sign of strength returning to the trend. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Trading CFD dengan Teknologi dan Kecepatan Lebih Baik IC Markets Mendaftar Undo The weekly RSI is turning up from support zones, adding confirmation. Traders may consider buying near ₹250 with a stop-loss at ₹244 and a short-term target of ₹260. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Business Standard
16-05-2025
- Business
- Business Standard
Jubilant Pharmova jumps after reporting turnaround Q4 performance
Jubilant Pharmova rallied 4.54% to Rs 947.05 after the company reported net profit of Rs 153.60 crore in Q4 FY25 compared with net loss of Rs 58.60 crore in Q4 FY24. Revenue from operations increased 9.7% YoY to Rs 1,915.80 crore in Q4 FY25. The company reported pre-tax profit of Rs 206 crore in Q4 FY25 as against pre-tax loss of Rs 53.70 crore in Q4 FY24. EBITDA jumped 23% to Rs 357 crore during the quarter compared with Rs 289 crore in Q4 FY24. EBITDA margin expanded 210 bps to 18.4% in Q4 FY25 as against 16.3% in Q4 FY24. In Q4 FY25, radiopharmaceuticals revenue grew by 15% YoY to Rs 296 crore, while revenue from radio pharmacy increased 7% YoY to Rs 600 crore in Q4 FY25. Revenue from Allergy Immunotherapy rose 2% YoY to Rs 192 crore and CDMO sterile injectables grew by 31% YoY to Rs 340 crore during the quarter . Contract research, development and manufacturing organisation (CRDMO) revenue stood at Rs 338 crore in Q4 FY25, up 19.86% YoY. The generics business reported revenue of Rs 157 crore in Q4 FY25, reflecting a 22% YoY decline. On full year basis, the companys consolidated net profit surged 988.7% to Rs 839.40 crore on 8.2% increase in revenue from operations to Rs 7,192.10 crore in FY25 over FY24. On the outlook front, in the Radiopharmaceuticals business, the company expects continued growth in Ruby-Fill installations. It remains on track to launch multiple new products in PET and SPECT imaging between FY27 and FY29. The dosing for the Phase 2 clinical trial of MIBG has been completed, and the data package is being prepared for submission to the US FDA by the second half of FY26. On the therapeutic front, over 10 new products are expected to be commercially available starting in 2029, supporting the expansion of the PET imaging industry. The proposed investment in six radiopharmacies is progressing, with commercial operations expected to begin from FY28 onwards. In the Allergy Immunotherapy segment, the company, as the sole supplier of Venom in the US, is working to expand the market by enhancing customer awareness. Revenue continues to grow in the US allergenic extracts business, and efforts are underway to penetrate markets beyond the US. In the CDMO Sterile Injectables segment, the capacity expansion at the Spokane, Washington facility is on schedule. Line 3 and Line 4 are expected to commence commercial production in late FY26 and FY28, respectively. Peak utilisation for Line 3 is now anticipated within three years of commercial launch, ahead of the earlier estimate of four years. In the CRDMO business, the medium-term outlook continues to be positive. In the short term, the business is trying to diversify its customer base and for the medium term, it is adding development capabilities in addition to research and manufacturing. In the CDMO API segment, efforts are concentrated on improving capacity utilisation through CDMO projects and custom generics manufacturing. In the Generics business, the company plans to launch six to eight products per annum in across US and non-US international markets. Export volumes to the US are being scaled up gradually and meaningfully, with increased contributions expected from contract manufacturing partners. The business aims to enhance profitability and return to growth in FY26. In the Proprietary Novel Drugs segment, interim data from the Phase 2 trial of JBI-802 is anticipated in FY26. Shyam. S. Bhartia, chairman Jubilant Pharmova and Hari S Bhartia, co-chairman & non-executive director, said, We are pleased to announce revenue of Rs 7,235 crore in FY25, growth of 8% over last year. We delivered robust revenue growth across Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables and CRDMO businesses. EBITDA grew by 24% to Rs 1,230 crore on the back of strong operating performance across all business units. EBITDA margins for the year expanded by 220 basis points. Reported PAT grew by 1,050% to Rs 836 crore, while normalised PAT grew by 112% to Rs 415 crore on the back of improved operating performance and reduced finance cost. Net Debt / EBITDA reduced from 2.5x in Mar24 to 1.1x in Mar25 on the back of voluntary debt prepayment of USD 125 million in FY25. In Feb2025, we outlined our Vision 2030, which is to double our revenues from FY24 to FY30, improve EBITDA margins to 23% to 25% range, reduce Net debt to zero and grow Return on Capital to high teens. Our FY25 financial performance takes us one-step closer to our Vision. During the year, the company started distributing Pylarify, an industry leading prostate cancer diagnostic imaging agent from PET radiopharmacies, completed Media Fills on Line 3 in CDMO Sterile Injectables, added strategic capabilities in the area of Biologics and Antibody drug conjugates in Drug Discovery, reached profitability in the Generics business and dosed first patients in JBI-802 and JBI-778 clinical trials. The large innovator pharma companies, for their US requirements, are now looking to create an alternate manufacturing site in the US as a risk management measure in the event of tariff imposed by the US govt. Therefore, the company is starting to see excellent traction in the CDMO Sterile Injectable business for new lines in the Spokane facility. We expect to reach peak utilisation for Line 3 in 3 years from start of commercial production vs 4 years, expected earlier." Meanwhile, the companys board recommended a final dividend of Rs 5 per share of Re 1 each for FY25. The dividend, if approved by the shareholders, will be paid within 30 days from the date of the Annual General Meeting. The company has fixed the record date as Friday, 25 July 2025, for the purpose of final dividend payment. Jubilant Pharmova is a globally present company engaged in radiopharmaceuticals, allergy immunotherapy, CDMO sterile injectables, contract research, development and manufacturing (CRDMO), generics, and proprietary novel drugs businesses.
Business Standard
16-05-2025
- Business
- Business Standard
Jubilant Pharmova reports consolidated net profit of Rs 153.60 crore in the March 2025 quarter
Sales rise 9.70% to Rs 1915.80 crore Net profit of Jubilant Pharmova reported to Rs 153.60 crore in the quarter ended March 2025 as against net loss of Rs 58.60 crore during the previous quarter ended March 2024. Sales rose 9.70% to Rs 1915.80 crore in the quarter ended March 2025 as against Rs 1746.40 crore during the previous quarter ended March 2024. For the full year,net profit rose 988.72% to Rs 839.40 crore in the year ended March 2025 as against Rs 77.10 crore during the previous year ended March 2024. Sales rose 8.24% to Rs 7192.10 crore in the year ended March 2025 as against Rs 6644.80 crore during the previous year ended March 2024. Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 1915.801746.40 10 7192.106644.80 8 OPM % 18.0215.54 - 16.3113.56 - PBDT 304.50216.20 41 989.70721.30 37 PBT 209.30115.20 82 621.10339.40 83 NP 153.60-58.60 LP 839.4077.10 989
Yahoo
16-05-2025
- Business
- Yahoo
India's Jubilant Pharmova posts surge in profit on demand for radiopharma medicines
(Reuters) -India's Jubilant Pharmova reported a surge in its fourth-quarter adjusted profit on Friday, driven by strong demand for its drugs with radioactive ingredients, used to treat cancer and other diseases. The drugmaker's consolidated profit before exceptional items and taxes rose 82% year-on-year to 2.09 billion rupees ($24.4 million) in the quarter ended March 31. Its net profit was 1.54 billion rupees in the quarter, compared with a year-ago loss of 586 million rupees, which included a 1.69-billion-rupee impairment charge for closing a plant in the U.S. Revenue rose 10% year-over-year to 19.29 billion rupees, lifted by a 9.5% jump in revenue from the radiopharma segment, which accounted for nearly 46% of the total revenue. The drugmaker, which makes and supplies radiopharmaceuticals used to diagnose and treat cancer and other diseases such as hyperthyroidism and lung diseases, has a network of 52 radio-pharmacies in the United States. This field is highly regulated and complex, thus limiting competition and benefiting companies such as Jubilant Pharmova, analysts said. Revenue from contract manufacturing, the company's second-biggest segment that makes sterile injectables, also jumped 33%. Revenue from its generics business, however, fell 22%. ($1 = 85.5930 Indian rupees) Sign in to access your portfolio
